Recordati Industria Chimica e Farmaceutica SpA represents values of excellence, innovation, and commitment to patient care in the pharmaceutical industry. As a leading global healthcare company, Recordati focuses on researching, developing, and marketing high-quality pharmaceuticals and treatments. With a strong dedication to scientific research, the company strives to improve patients' lives by providing effective and safe medications. Recordati's corporate philosophy emphasizes ethical conduct, transparency, and long-term relationships with healthcare professionals and patients. By maintaining a customer-centric approach, the company has built a reputation for delivering trusted and reliable products. Through its continuous pursuit of advancements and patient-focused values, Recordati Industria Chimica e Farmaceutica SpA remains a key player in the pharmaceutical sector.

Recordati Industria Chimica e Farmaceutica SpA is primarily present in various countries and regions worldwide. The company has a strong presence in Italy, which serves as its headquarters. Additionally, Recordati has established operations and subsidiaries in several countries across Europe, including Spain, France, Germany, and the United Kingdom. Outside of Europe, the company has a significant presence in the United States, Canada, and Mexico, making it an important player in the North American pharmaceutical market. With its extensive global reach, Recordati Industria Chimica e Farmaceutica SpA is continuously expanding its presence and market share in the pharmaceutical industry.

Recordati Industria Chimica e Farmaceutica SpA has achieved several significant milestones throughout its history. Founded in 1926, the company has established itself as a leading player in the pharmaceutical industry. Some of the notable achievements include successfully developing and launching innovative drugs, expanding its global presence through strategic partnerships and acquisitions, and consistently delivering strong financial performance. Recordati has also received numerous awards and recognitions for its contributions to the healthcare sector. With a strong focus on research and development, the company continues to innovate and create value for its stakeholders.

Recordati Industria Chimica e Farmaceutica SpA is an Italian pharmaceutical company with a rich history and extensive background. Established in 1926, Recordati has become a global leader in the pharmaceutical industry. The company specializes in the development, manufacturing, and marketing of innovative drugs and medical treatments. With a focus on research-driven solutions, Recordati has built a strong reputation for providing high-quality products that improve the health and well-being of patients worldwide. Over the years, they have expanded their presence across various therapeutic areas, including cardiovascular, urological, and rare diseases. As an esteemed pharmaceutical entity, Recordati Industria Chimica e Farmaceutica SpA continues to contribute significantly to the advancement of healthcare globally.

The main competitors of Recordati Industria Chimica e Farmaceutica SpA in the market include large pharmaceutical companies such as Novartis, Pfizer, and Sanofi. These companies operate in similar therapeutic areas and have significant market presence globally. However, Recordati distinguishes itself through its focus on niche markets, its expertise in rare diseases, and its strong distribution network. By maintaining a diversified product portfolio and continuously innovating, Recordati remains competitive in a dynamic pharmaceutical industry. Serving as a leading pharmaceutical company, Recordati Industria Chimica e Farmaceutica SpA faces competition from well-established players in the market.

Recordati Industria Chimica e Farmaceutica SpA is primarily active in the pharmaceutical industry. With a focus on research, development, manufacturing, and marketing of pharmaceutical products, Recordati is a leading player in the global healthcare sector. The company specializes in prescription drugs, with a portfolio that spans multiple therapeutic areas such as cardiovascular, central nervous system, urological, and rare diseases. Recordati's commitment to scientific innovation and patient care drives its success in delivering high-quality pharmaceutical solutions worldwide. As a reputable player in the pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA continues to contribute to advancements in healthcare and improve the quality of life for patients around the globe.

Recordati Industria Chimica e Farmaceutica SpA operates as a leading international pharmaceutical company, specializing in research, development, manufacturing, and marketing of innovative and niche pharmaceutical products. The company's business model revolves around identifying unmet medical needs and developing targeted therapies. Recordati focuses on niche therapeutic areas such as rare diseases, genitourinary disorders, and cardiovascular diseases. By leveraging its global presence and extensive sales network, Recordati distributes its products to over 130 countries, ensuring widespread availability and patient access to its treatments. Through its commitment to innovation, quality, and patient care, Recordati Industria Chimica e Farmaceutica SpA continues to excel in the pharmaceutical industry.

مُعامل القيمة السوقية إلى الأرباح لـ Recordati Industria Chimica e Farmaceutica SpA هو ٢٠٫٨٩.

مُعامِل القيمة إلى المبيعات Recordati Industria Chimica e Farmaceutica SpA هو ٤٫٤٥.

نقاط جودة AlleAktien لـ Recordati Industria Chimica e Farmaceutica SpA هي 10/10.

المتوقعة Recordati Industria Chimica e Farmaceutica SpA الإيرادات هي ٢٫٣٥ مليارات EUR.

صافي الربح المتوقعة Recordati Industria Chimica e Farmaceutica SpA هو ٥٠٠٫٥٩ مليون. EUR.

The Recordati Industria Chimica e Farmaceutica SpA is a leading company in the pharmaceutical industry. Its goal is to provide innovative medications and treatment methods to help people with specific conditions. The business model of Recordati includes three main focuses: research and development, production, and marketing. In the research and development field, the company continuously works on developing new active ingredients and therapies to improve people's quality of life. Recordati's product range includes a variety of medications in different categories such as cardiology, urology, dermatology, and pain management. Some of the company's well-known products are Carbaglu, Cardiren, Ornilox, and Cystadrops. In terms of production, Recordati has a state-of-the-art infrastructure to ensure that all products are manufactured according to the highest quality standards. The company utilizes a combination of internal and external production facilities to maximize efficiency and flexibility. Recordati also has a wide distribution network to sell its products worldwide. The company operates in more than 100 countries and collaborates closely with various partners to ensure that patients around the world have access to high-quality medications. As part of its business strategy, Recordati has conducted various acquisitions and acquisitions to expand its market position and diversify its offerings. For example, the company recently acquired Tonipharm and Rottapharm Spa. Overall, Recordati has a strong and stable business strategy focused on long-term growth and value creation for all stakeholders. The company is expected to continue improving its production technologies and distribution systems and develop more innovative products to maintain a leading position in the pharmaceutical market.

يوزع Recordati Industria Chimica e Farmaceutica SpA أرباحًا قدرها ١٫١٢ EUR من خلال 2 عمليات توزيع موزعة على مدار السنة.

Recordati Industria Chimica e Farmaceutica SpA يوزع أرباحًا 2 مرة في السنة.

الرمز الدولي للأوراق المالية الخاص بـRecordati Industria Chimica e Farmaceutica SpA هو IT0003828271.

رمز WKN لـ Recordati Industria Chimica e Farmaceutica SpA هو A0EABR.

الرمز المُختصر لـ Recordati Industria Chimica e Farmaceutica SpA هو REC.MI.

خلال آخر 12 شهراً، دفعت Recordati Industria Chimica e Farmaceutica SpA توزيعات أرباح بقيمة ١٫١٧ EUR . وهذا يعادل عائد توزيعات أرباح يقارب ٢٫٣٠ %. ومن المتوقع أن تدفع Recordati Industria Chimica e Farmaceutica SpA خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ١٫٢٥ EUR.

نسبة توزيعات الأرباح الحالية لـ Recordati Industria Chimica e Farmaceutica SpA هي ٢٫٣٠ %.

Recordati Industria Chimica e Farmaceutica SpA يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر ديسمبر, يونيو, ديسمبر, يونيو.

Recordati Industria Chimica e Farmaceutica SpA دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة ١٫٢٥ EUR. وهذا يعادل عائد توزيعات أرباح قدره ٢٫٤٥ %.

Recordati Industria Chimica e Farmaceutica SpA يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ٠٫٦٣ EUR من Recordati Industria Chimica e Farmaceutica SpA المُعلن عنها في ٢٢‏/٥‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٠‏/٥‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٢‏/٥‏/٢٠٢٤.

في العام 2023، وزعت Recordati Industria Chimica e Farmaceutica SpA ١٫١٢ EUR كأرباح أسهم.

يتم توزيع أرباح Recordati Industria Chimica e Farmaceutica SpA بالعملة EUR.